CN103562725B - 川崎病的诊断标志物和治疗靶点 - Google Patents

川崎病的诊断标志物和治疗靶点 Download PDF

Info

Publication number
CN103562725B
CN103562725B CN201280024575.6A CN201280024575A CN103562725B CN 103562725 B CN103562725 B CN 103562725B CN 201280024575 A CN201280024575 A CN 201280024575A CN 103562725 B CN103562725 B CN 103562725B
Authority
CN
China
Prior art keywords
biomarker
level
filamin
protein
meprin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280024575.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103562725A (zh
Inventor
亚历克斯·肯特赛斯
苏姗·金
汉诺·斯泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Priority to CN201610498798.6A priority Critical patent/CN106053835A/zh
Publication of CN103562725A publication Critical patent/CN103562725A/zh
Application granted granted Critical
Publication of CN103562725B publication Critical patent/CN103562725B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201280024575.6A 2011-04-15 2012-04-13 川崎病的诊断标志物和治疗靶点 Expired - Fee Related CN103562725B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610498798.6A CN106053835A (zh) 2011-04-15 2012-04-13 川崎病的诊断标志物和治疗靶点

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161475936P 2011-04-15 2011-04-15
US61/475,936 2011-04-15
US201161579007P 2011-12-22 2011-12-22
US61/579,007 2011-12-22
PCT/US2012/033514 WO2012142409A2 (en) 2011-04-15 2012-04-13 Diagnostic markers and therapeutic targets of kawasaki disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610498798.6A Division CN106053835A (zh) 2011-04-15 2012-04-13 川崎病的诊断标志物和治疗靶点

Publications (2)

Publication Number Publication Date
CN103562725A CN103562725A (zh) 2014-02-05
CN103562725B true CN103562725B (zh) 2016-08-17

Family

ID=46208753

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610498798.6A Pending CN106053835A (zh) 2011-04-15 2012-04-13 川崎病的诊断标志物和治疗靶点
CN201280024575.6A Expired - Fee Related CN103562725B (zh) 2011-04-15 2012-04-13 川崎病的诊断标志物和治疗靶点

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610498798.6A Pending CN106053835A (zh) 2011-04-15 2012-04-13 川崎病的诊断标志物和治疗靶点

Country Status (8)

Country Link
US (1) US9869673B2 (enExample)
EP (2) EP3086121A1 (enExample)
JP (1) JP6072768B2 (enExample)
KR (1) KR20140034193A (enExample)
CN (2) CN106053835A (enExample)
AU (1) AU2012242684B2 (enExample)
CA (1) CA2833257A1 (enExample)
WO (1) WO2012142409A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3137907A4 (en) * 2014-05-02 2018-02-28 Momenta Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of kawasaki disease
WO2016014761A1 (en) * 2014-07-24 2016-01-28 Academia Sinica Diagnosis and treatment of kawasaki disease
KR102056405B1 (ko) * 2018-04-05 2019-12-16 (주)메디젠휴먼케어 Ebf2 유전자 다형성을 이용한 가와사키병 발병 예측 방법
CN110763845B (zh) * 2018-07-27 2022-10-28 成都市第三人民医院 一种检测蛋白标志物的配体在制备用于诊断结肠癌的产品中的用途和试剂盒
TWI704349B (zh) * 2019-06-17 2020-09-11 高雄榮民總醫院 蛋白質生物標記用以診斷川崎症的用途
JPWO2022071601A1 (enExample) * 2020-10-02 2022-04-07
CN116087519B (zh) * 2021-05-17 2025-03-14 郑州大学第一附属医院 一种用于高危人群贲门腺癌早期筛查的标志物及其应用
KR102705469B1 (ko) * 2022-05-30 2024-09-11 충남대학교산학협력단 불응성 가와사키병의 감별 진단을 위한 정보 제공 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093005A1 (en) * 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
US20090191575A1 (en) * 2006-06-05 2009-07-30 Makoto Watanabe Tumor marker and method for determination of the occurrence of cancerous disease
WO2010099918A1 (en) * 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
WO2007003594A1 (en) 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Screening methods for inhibitors of the metalloprotease meprin
JP4795037B2 (ja) 2006-02-01 2011-10-19 財団法人 神戸市地域医療振興財団 川崎病の判定方法及びそのためのキット
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191575A1 (en) * 2006-06-05 2009-07-30 Makoto Watanabe Tumor marker and method for determination of the occurrence of cancerous disease
US20090093005A1 (en) * 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
WO2010099918A1 (en) * 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Filamin C accumulation is a strong but nonspecific immunohistochemical marker of core formation in muscle;C.G. Bo¨nnemann, et al.;《Journal of the Neurological Sciences》;20031231;第206卷;第71-78页 *
Meprin A,the major matrix degrading enzyme in renal tubules，produces a novel nidogen fragment in vitro and in vivo;Patrick D.Walker,et al.;《Kidney International》;19981231;第53卷;第1673-1680页 *

Also Published As

Publication number Publication date
EP3086121A1 (en) 2016-10-26
WO2012142409A2 (en) 2012-10-18
AU2012242684B2 (en) 2017-04-20
JP6072768B2 (ja) 2017-02-01
WO2012142409A3 (en) 2013-02-28
EP2697653A2 (en) 2014-02-19
CN106053835A (zh) 2016-10-26
CN103562725A (zh) 2014-02-05
JP2014512014A (ja) 2014-05-19
US9869673B2 (en) 2018-01-16
KR20140034193A (ko) 2014-03-19
AU2012242684A1 (en) 2013-10-31
US20140161791A1 (en) 2014-06-12
CA2833257A1 (en) 2012-10-18
EP2697653B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
CN103562725B (zh) 川崎病的诊断标志物和治疗靶点
Richards et al. Characterization and peripheral blood biomarker assessment of anti–Jo‐1 antibody–positive interstitial lung disease
Staubli et al. Laboratory markers predicting severity of acute pancreatitis
Kentsis et al. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease
CN105556308B (zh) 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
US11041867B2 (en) ProADM and/or histones as markers indicating an adverse event
CN109564225B (zh) 作为指示不良事件的标志物的组蛋白和/或proADM
AU2017232081A1 (en) Acute kidney injury
Martin et al. Serum immunoglobulin G4 levels and Graves’ disease phenotype
Liu et al. Methodological evaluation and comparison of five urinary albumin measurements
CN106461673A (zh) 用于检测嗜铬粒蛋白a的免疫测定与抗体
JP4918556B2 (ja) サンプル中の被検体（抗原）および該被検体を標的とする治療用抗体を同時に免疫化学的に測定するためのイムノアッセイ（リカバリー・イムノアッセイ（ＲｅｃｏｖｅｒｙＩｍｍｕｎｏａｓｓａｙ））
JP2024516680A (ja) 敗血症の早期検出用のｉｌ６マーカーパネル
US8697368B2 (en) Diagnostic marker for lung cancer comprising HPαR as active ingredient
JP2006308576A (ja) 膵液による膵管内乳頭粘液性腺癌および膵臓癌の検出法及び検出キット
Yang et al. Development of a novel parallel determination platform: a feasibility study tested on a chemiluminescence device
HK1193650A (en) Diagnostic markers and therapeutic targets of kawasaki disease
CN107076758B (zh) 作为心力衰竭预后标志物的脑啡肽酶
WO2016205740A1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
Jiang et al. Association and predictive value of immunoglobulin and complement levels for incident coronary heart disease: a nested case-control study in Chinese adults
JP7640168B2 (ja) 夜尿症の患者の治療応答を予測する方法
US20250327815A1 (en) System and methods for diagnosing acute interstitial nephritis
US20230305010A1 (en) Timp1 as a marker for cholangiocarcinoma
JP2014505256A (ja) 急性冠動脈症候群後の心不全を検出し、予後を判定するためのガレクチン−３の使用
Kumar et al. High sensitive troponin as biomarker for coronary artery disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193650

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160817

Termination date: 20190413

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1193650

Country of ref document: HK